After COVID-19, BioNTech Plans To Develop an mRNA Vaccine To Prevent Malaria

BioNTech SE BNTX has announced that it plans to develop an mRNA-based vaccine to prevent Malaria, a mosquito-borne illness.
The Company aims to begin clinical trials for the shot by the end of 2022.
BioNTech said it would assess multiple vaccine candidates that target the circumsporozoite protein (CSP), as well as new antigens discovered in pre-clinical research.
Price Action: BNTX shares are up 3.72% at $292.44 during the market session on the last check Monday.